Komori
General Meetings of Shareholders4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of the Results of the 5th Annual General Meeting of Shareholders

At the 5th Annual General Meeting of Shareholders, all company proposals, Proposals 1 through 11, were approved, while shareholder proposal, Proposal 12, was rejected.

Worth reading
98Important
Scored from 1 of 4 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (5th)
2026
Jun 24
Date and time
Matters for resolution12 items
  1. Appropriation of surplus

  2. Partial Amendments to the Articles of Incorporation

  3. Election of 10 directors, excluding directors who are Audit and Supervisory Committee Members

  4. Election of 3 Directors who are Audit and Supervisory Committee Members

  5. Election of 1 Substitute Director who is an Audit & Supervisory Committee Member (Nishino Takeshi (西野武))

  6. Determination of the amount of compensation for directors, excluding directors who are Audit and Supervisory Committee Members

  7. Determination of the amount of compensation for directors who are Audit and Supervisory Committee Members

  8. Revision of the restricted stock compensation system for directors, excluding directors who are Audit and Supervisory Committee Members and outside directors

  9. Determination of compensation for the grant of restricted stock to outside directors, excluding directors who are Audit and Supervisory Committee Members

  10. Election of the accounting auditor

  11. Approval of the implementation of countermeasures if Dalton and others conduct a large-scale purchase of the Company’s shares without complying with the Company’s response policy, in light of the current situation (an emergency) in which Dalton and others are contemplating such large-scale purchase actions

  12. Election of 2 directors who are not Audit and Supervisory Committee Members

Shareholder Proposal

Yes. The proponents were James B. Rosenwald III and Hayashi Shiro (林史朗). They proposed the election of 2 Directors who are not Audit & Supervisory Committee Members; the Board of Directors' position on the proposal is not stated in the main text.

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee15 candidates for Director (10 under Proposal 3, 3 under Proposal 4, 1 under Proposal 5, and 2 under Proposal 12; Proposal 5 concerns a substitute candidate). The numbers of new and outside candidates are Not disclosed.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (5th)
Date and time24 June 2026
Matters for resolutionProposal No. 1: Appropriation of surplus, Proposal No. 2: Partial Amendments to the Articles of Incorporation, Proposal No. 3: Election of 10 directors, excluding directors who are Audit and Supervisory Committee Members, Proposal No. 4: Election of 3 Directors who are Audit and Supervisory Committee Members, Proposal 5: Election of 1 Substitute Director who is an Audit & Supervisory Committee Member (Nishino Takeshi (西野武)), Proposal No. 6: Determination of the amount of compensation for directors, excluding directors who are Audit and Supervisory Committee Members, Proposal No. 7: Determination of the amount of compensation for directors who are Audit and Supervisory Committee Members, Proposal No. 8: Revision of the restricted stock compensation system for directors, excluding directors who are Audit and Supervisory Committee Members and outside directors, Proposal No. 9: Determination of compensation for the grant of restricted stock to outside directors, excluding directors who are Audit and Supervisory Committee Members, Proposal No. 10: Election of the accounting auditor, Proposal No. 11: Approval of the implementation of countermeasures if Dalton and others conduct a large-scale purchase of the Company’s shares without complying with the Company’s response policy, in light of the current situation (an emergency) in which Dalton and others are contemplating such large-scale purchase actions, Proposal No. 12: Election of 2 directors who are not Audit and Supervisory Committee Members
Shareholder ProposalYes. The proponents were James B. Rosenwald III and Hayashi Shiro (林史朗). They proposed the election of 2 Directors who are not Audit & Supervisory Committee Members; the Board of Directors' position on the proposal is not stated in the main text.
Director nominee15 candidates for Director (10 under Proposal 3, 3 under Proposal 4, 1 under Proposal 5, and 2 under Proposal 12; Proposal 5 concerns a substitute candidate). The numbers of new and outside candidates are Not disclosed.
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company stated that it views the results as indicating that it has gained shareholders' understanding of its management policies, and that it will pursue sustainable growth and enhance corporate value over the medium to long term under the newly elected management team.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Results of the 5th Annual General Meeting of Shareholders | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori